Prica A, et al. - Given that oncologists often rely on their clinical impression and the patient's age to make treatment decisions in elderly patients with lymphoma, researchers sought for more objective measures that may be more accurate and reproducible in predicting chemotherapy eligibility and toxicity. In this single-center pilot feasibility study 30 patients (≥70 yrs; 59% male) with lymphoma, planned for systemic chemotherapy, completed geriatric tools (eg. Hurria and CRASH questionnaires, gait speed test, and grip strength, CSHA Frailty Scale). The patients underwent physical tests that were repeated with each cycle. As per outcomes, full-dose systemic chemotherapy treatment can be provided to older patients, but with high toxicity rate. Toxicity could be predicted using the Hurria tool, which is much shorter to administer. Chemotherapy toxicity could be most robustly predicted via the CSHA Frailty, which is a very simple measure to administer. They recommend measuring these simple tools in all lymphoma patients.